PharmGKB ID	Variant	Literature	Genes	Association	Significance	P-Value	# of Cases	# of Controls	Biogeographical Groups	Phenotype Categories	Pediatric	More Details	Molecules
1184749213	rs1801253	PMID:18797399	ADRB1	Allele C is not associated with response to citalopram in people with Depressive Disorder, Major as compared to allele G.	no	> 0.05	730		European	Efficacy	false	No significant differences in the number of patients who were classified as nonresponders, responders or remitters were seen between either the genotypes (CC, CG, GG) or the alleles (C, G), in either European American or African American populations. Remitters achieved a Quick Inventory for Depression Scale, Change 16 Item version (QIDS-C16) score of <= 5 at the last treatment visit. Responders achieved at least a 50% reduction in baseline QIDS-C16 score at the last treatment visit. Nonresponders did not achieve even a 40% reduction in baseline QIDS-C16 score.	citalopram
981476225	rs4148740	PMID:18215618	ABCB1	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.	yes	= 0.0029	260		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1183701647	CYP2C19 poor metabolizer	PMID:8835706	CYP2C19	CYP2C19 poor metabolizers is not associated with increased risk of intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.	no		69		Unknown	Toxicity	false	Six patients were poor metabolizers of mephenytoin, with an S/R ratio of mephenytoin > 0.8. Of the six poor metabolizers of mephenytoin, three were responders and three were nonresponders.	citalopram
1446908220	CYP2C19*1; CYP2C19*2	PMID:26343256	CYP2C19	CYP2C19 *2 is associated with decreased metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	yes	< 0.05	50		Unknown	Metabolism/PK	false	Mean plasma concentrations and the mean dose-corrected plasma levels of desmethylcitalopram were significantly lower in *2 carriers as compared to *1/*1. Mean metabolic ratio (MR, CIT/DCIT) was significantly higher in the CYP2C19*1/*2 + CYP2C19*2/*2 genotypes. Citalopram concentration and citalopram dose are not different between *2 carriers and *1/*1.	citalopram
1184748190	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:25154506	CYP2C19	CYP2C19 *2/*2 + *3/*3 + *2/*3 (assigned as poor metabolizers phenotype) is associated with increased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	yes	< 0.0001	847		Multiple groups, Asian and White	Metabolism/PK	false	Compared to subjects with the EM/EM (CYP2C19*1/*1) genotype, the exposure to (es)citalopram increased by 95 % (95 % CI 40-149, p < 0.0001) in the poor metabolizer (PM)/PM (CYP2C19*2 or *3/*2 or *3). For this meta-analyis of 16 studies (in Asian and White), the studies must meet the following criteria to be included: (1) all subjects received at least one single dose of citalopram or escitalopram orally; (2) either genotyping or phenotyping of CYP2C19 was performed in all subjects; (3) citalopram or escitalopram exposure level [mean and standard deviation (SD)] was presented separately for the EM/EM genotype group and at least one of the following groups: UM/UM, UM/EM, UM/PM, EM/PM, PM/PM; and (4) if polymorphism was only assessed by phenotyping, citalopram or escitalopram exposure was reported separately for the EMpheno and PMpheno groups.	citalopram; escitalopram
982023052	rs6311	PMID:23221997	HTR2A	Allele T is not associated with remission rates when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.	no	= 0.55	159		European	Efficacy	false		citalopram
1183701639	CYP2C19 poor metabolizer	PMID:8835706	CYP2C19	CYP2C19 poor metabolizer is associated with increased plasma ratio citalopram (CIT)/N-desmethylCIT (DCIT) when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer.	yes	= 0.0001	69		Unknown	Metabolism/PK	false	Phenotyped with mephenytoin. Three patients were poor metabolizers of dextromethorphan, with a metabolic ratio dextrorphan/dextromethorphan > 0.3, and six patients were poor metabolizers of mephenytoin, with an S/R ratio of mephenytoin > 0.8. Of the six poor metabolizers of mephenytoin, three were responders and three were nonresponders.	citalopram
1184169374	CYP2D6*1; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*10; CYP2D6*17; CYP2D6*41	PMID:23545896	CYP2D6	CYP2D6 *1/*1 + *1/*10 + *1/*17 + *1/*3 + *1/*4 + *1/*41 + *1/*5 is not associated with side effects when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *10/*10 + *10/*41 + *3/*4 + *3/*41 + *4/*10 + *4/*4.	no	= 0.619	184		Multiple groups, predominantly European ancestry (90.2%)	Toxicity	false	The association is for impact of CYP2D6 (P=0.619) or CYP2C19 (P=0.391) on the occurrence of significant side effects in all trials overall (defined see below). Patients had undergone one or more trials of serotonin reuptake inhibitors (including fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram or escitalopram), venlafaxine, mirtazapine, duloxetine or clomipramine. articipants had multiple trials of medications, individuals were defined as an overall responder (that is, to medications in general) if they reported response to greater than or equal to50% of all drug trials recalled. Correspondingly, patients who reported benefits from <50% of medications tried were deemed overall nonresponders. A similar approach was taken for side effects.	citalopram; clomipramine; duloxetine; escitalopram; fluoxetine; fluvoxamine; mirtazapine; paroxetine; sertraline; venlafaxine
981476235	rs10280101	PMID:18215618	ABCB1	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.	yes	= 0.0053	257		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
982023044	rs1800532	PMID:23221997	TPH1	Allele T is not associated with remission rates when treated with citalopram in people with Depressive Disorder, Major as compared to allele G.	no	= 0.56	159		European	Efficacy	false		citalopram
1450931573	rs6311	PMID:30221791	HTR2A	Genotype CC is associated with increased likelihood of Nausea and Vomiting due to citalopram in people with Depressive Disorder, Major as compared to genotypes CT + TT.	yes	= 0.03	63		Unknown	Toxicity	false	The GG genotype was significantly more frequent in patients who experience citalopram-induced nausea and vomiting. This variant is referred to in the paper as the -1438 A/G SNP. Please note that alleles have been complemented to the positive strand.	citalopram
1184749202	rs1801252	PMID:18797399	ADRB1	Allele A is not associated with response to citalopram in people with Depressive Disorder, Major as compared to allele G.	no	> 0.05	730		European	Efficacy	false	No significant differences in the number of patients who were classified as nonresponders, responders or remitters were seen between either the genotypes (AA, AG, GG) or the alleles (A, G), in either European American or African American populations. Remitters achieved a Quick Inventory for Depression Scale, Change 16 Item version (QIDS-C16) score of <= 5 at the last treatment visit. Responders achieved at least a 50% reduction in baseline QIDS-C16 score at the last treatment visit. Nonresponders did not achieve even a 40% reduction in baseline QIDS-C16 score.	citalopram
1184749196	rs929493	PMID:18797399	SLC18A2	Allele C is not associated with response to citalopram in people with Depressive Disorder, Major as compared to allele T.	no	> 0.05	730		European	Efficacy	false	No significant differences in the number of patients who were classified as nonresponders, responders or remitters were seen between either the genotypes (CC, CT, TT) or the alleles (C, T), in either European American or African American populations. Remitters achieved a Quick Inventory for Depression Scale, Change 16 Item version (QIDS-C16) score of <= 5 at the last treatment visit. Responders achieved at least a 50% reduction in baseline QIDS-C16 score at the last treatment visit. Nonresponders did not achieve even a 40% reduction in baseline QIDS-C16 score.	citalopram
1449731960	rs1045642	PMID:29723928	ABCB1	Genotype AA is not associated with exposure to citalopram in healthy individuals as compared to genotypes AG + GG.	no	> 0.05	17		Unknown	Metabolism/PK	false	Please note that alleles have been complemented to the positive strand. Genotype at rs1045642 had no statistically significant association with AUC, Cmax, half-life, Tmax, Cl/F or Vd/F of citalopram.	citalopram
982023066	rs6318	PMID:23221997	HTR2C	Allele G is not associated with response when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.	no	= 0.27	159		European	Efficacy	false		citalopram
981476245	rs7787082	PMID:18215618	ABCB1	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele G.	yes	= 0.0046	257		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1183617434	CYP2D6*1; CYP2D6*4	PMCID:PMC2291379	CYP2D6	CYP2D6 *4/*4 is associated with decreased dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Depression as compared to CYP2D6 *1/*1.	yes	= 0.03	833		European	Dosage,Efficacy	false	(*4*4 vs. *1*1; this SNP was the only SNP assayed and this method could not detect *5.) SSRIs were grouped together for this analysis (32.5 % of patients were taking paroxetine; 13.4% fluvoxamine;11.6% fluoxetine; 7.3% sertraline;4.6% citalopram;0.1% escitalopram.  Mean SSRI dose was significantly lower at the 3rd  prescription (difference 0.17 DDD) but not significant for the following prescriptions.   Genotypes were not in Hardy-Weinberg equilibrium; frequency below is for a larger population that included patients treated with other antidepressants.	citalopram; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline
1183619994	CYP2D6*1; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*6	PMCID:PMC2268970	CYP2D6	CYP2D6 *3 +*4 + *5 + *6 are not associated with differences in remission or tolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2D6 *1.	no		1046		Multiple groups	Efficacy,Toxicity	false	CYP2D6*5, *3, *4, *6, *7, *8, *9 were genotyped	citalopram
1183619732	CYP2C19*1; CYP2C19*2	PMID:16418702	CYP2C19	CYP2C19 *1/*2 is associated with increased median concentration/dose ratio and median parent drug/metabolite ratio when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	yes	= 0.01	83		European	Metabolism/PK	false		citalopram; escitalopram
1183701655	CYP2D6 poor metabolizer	PMID:8835706	CYP2D6	CYP2D6 poor metabolizer is associated with increased ratio of desmethylCIT/N-didesmethylCIT plasma when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizer.	no		69		Unknown	Metabolism/PK	false	No statistics due to low sample number but there was a significant positive correlation between the metabolic ratio of dextromethorphan and the ratio DCIT/N-didesmethylCIT in plasma (p < 0.001). Three patients were poor metabolizers of dextromethorphan, with a metabolic ratio dextrorphan/dextromethorphan > 0.3.	citalopram
1184472450	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:14624186	SLC6A4	SLC6A4 HTTLPR long form (L allele) is not associated with response to citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	no	= 0.68	130		Unknown	Efficacy	false	Citalopram treatment: mean initial dose: 26.4; range:20-40 mg/day. Genotyped using PCR and length determination via gel.  Clinical response to citalopram at 4th week, 89 patients (68%) were classified as Responders (Rp) and 42 (32%) as Non Responders (N-Rp). Genotype distribution for the 5-HTTLPR polymorphism showed no significant differences between both groups ([chi]2 = 0.77, P = 0.68). No significant differences between both subgroups of patients in the distribution of homozygous S/S versus allele L carriers were found either ([chi]2 = 0.03, P = 0.87).	citalopram
1184483970	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:20640435	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased likelihood of remission when treated with citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	yes	= 0.04	85		European	Efficacy	false	Treatment outcome was assessed with the MADRS scale.	citalopram; fluoxetine; paroxetine
1184749190	rs363343	PMID:18797399	SLC18A2	Allele A is not associated with response to citalopram in people with Depressive Disorder, Major as compared to allele C.	no	> 0.05	730		European	Efficacy	false	No significant differences in the number of patients who were classified as nonresponders, responders or remitters were seen between either the genotypes (AA, AC, CC) or the alleles (A, C), in either European American or African American populations. Remitters achieved a Quick Inventory for Depression Scale, Change 16 Item version (QIDS-C16) score of <= 5 at the last treatment visit. Responders achieved at least a 50% reduction in baseline QIDS-C16 score at the last treatment visit. Nonresponders did not achieve even a 40% reduction in baseline QIDS-C16 score.	citalopram
1447979349	rs11580409	PMCID:PMC5003027	ERICH3	Allele A is associated with increased response to citalopram and escitalopram in people with Depressive Disorder as compared to allele C.	yes	= 0.022	865		Unknown	Efficacy	false	This is one of SNP in a cluster (rs11580409 and rs11210490 and rs696692) that showed some association with plasma serotonin concentrations and was suspected to be associated with SSRI clinical response. When tested in the PGRN-AMPS GWAS and in two independent SSRI response GWAS (STAR*D and ISPC) rs11580409 in ERICH3 was associated with response at 4 weeks in the ISPC population and response at 6 weeks in the STAR*D population but not associated with response in the PGRN-AMPS cohort. Baseline plasma serotonin concentrations before SSRI therapy, as well as changes in serotonin were used as a biomarker for response to SSRIs and GWAS was done w/respect to changes in plasma serotonin concentration.	citalopram; escitalopram
982023060	rs6311	PMID:23221997	HTR2A	Allele T is not associated with response when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.	no	= 0.25	159		European	Efficacy	false		citalopram
1184749184	rs363390	PMID:18797399	SLC18A2	Allele C is not associated with response to citalopram in people with Depressive Disorder, Major as compared to allele G.	no	> 0.05	730		European	Efficacy	false	No significant differences in the number of patients who were classified as nonresponders, responders or remitters were seen between either the genotypes (CC, CG, GG) or the alleles (C, G), in either European American or African American populations. Remitters achieved a Quick Inventory for Depression Scale, Change 16 Item version (QIDS-C16) score of <= 5 at the last treatment visit. Responders achieved at least a 50% reduction in baseline QIDS-C16 score at the last treatment visit. Nonresponders did not achieve even a 40% reduction in baseline QIDS-C16 score.	citalopram
1184169142	CYP2D6*1; CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*10; CYP2D6*17; CYP2D6*41	PMID:23545896	CYP2D6	CYP2D6 *1/*1 + *1/*10 + *1/*17 + *1/*3 + *1/*4 + *1/*41 + *1/*5 is not associated with treatment response when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2D6 *10/*10 + *10/*41 + *3/*4 + *3/*41 + *4/*10 + *4/*4.	no	= 0.743	184		Multiple groups, predominantly European ancestry (90.2%)	Efficacy	false	The association is for impact of CYP2D6 (P=0.743) or CYP2C19 (P=0.939) on overall response (defined see below). Patients had undergone one or more trials of serotonin reuptake inhibitors (including fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram or escitalopram), venlafaxine, mirtazapine, duloxetine or clomipramine. articipants had multiple trials of medications, individuals were defined as an overall responder (that is, to medications in general) if they reported response to greater than or equal to50% of all drug trials recalled. Correspondingly, patients who reported benefits from <50% of medications tried were deemed overall nonresponders.	citalopram; clomipramine; duloxetine; escitalopram; fluoxetine; fluvoxamine; mirtazapine; paroxetine; sertraline; venlafaxine
1183921586	CYP2D6*1; CYP2D6*1xN; CYP2D6*2	PMID:22775532	CYP2D6	CYP2D6 *1/*1xN + *1xN/*2 (assigned as ultrarapid metabolizer phenotype phenotype) is not associated with differences in treatment response when treated with citalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Obsessive-Compulsive Disorder as compared to CYP2D6 normal metabolizer.	no	> 0.05	39		Unknown	Efficacy	false	CYP2D6 metabolizer status had no significant effect on clinical response (p>0.05).32 patients were CYP2D6 EMs, 2 were UMs, 4 were IMs, and 1 patient was a PM. Exploratory association analysis of response to all 108 drug trials found a significant effect of CYP2D6 metabolizer status on response (Fisher's exact test: p=0.021) when comparing the patients with reduced CYP2D6 activity (IMs and PMs) to EMs or UMs, but no information regarding the direction of the association is given. AmpliChip CYP450 test, which detects up to 33 alleles, including 7 duplications in the CYP2D6 and 3 alleles in the CYP2C19 gene. PM, IM, EM, or UM status for CYP2D6 and PM or EM status for CYP2C19 using phenotyping software available with the AmpliChip CYP450 test.	citalopram; fluoxetine; fluvoxamine; paroxetine; sertraline
1183848115	rs1065852	PMCID:PMC4137829	CYP2D6	Allele A is associated with plasma concentration of S-didesmethyl-citalopram when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to allele G.	yes	= 2.0E-16	435		European	Other	false	direction of the association was not given, p = 2.0E-16	citalopram; escitalopram
1449717838	CYP2C19 poor metabolizer phenotype	PMID:30135031	CYP2C19	CYP2C19 poor metabolizer phenotype is not associated with risk of adverse events due to citalopram or escitalopram in people with as compared to CYP2C19 normal metabolizer phenotype.	no		4135		European	Toxicity	false	There was no significant difference in total side effects burden across multiple timepoints between normal metabolizers and poor metabolizers. Metabolizer phenotypes were assigned based on genotyping for the *1, *2 and *17 alleles.	citalopram; escitalopram
1451351720	rs6313	PMID:27324805	HTR2A	Allele A is not associated with Drug Toxicity when treated with citalopram in children with Anxiety Disorders or Depressive Disorder, Major as compared to allele G.	no		87		Near Eastern	Toxicity	true		citalopram
981476266	rs4148739	PMID:18215618	ABCB1	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.	yes	= 0.0029	261		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1447979364	rs11947402	PMCID:PMC5003027	TSPAN5	Allele G is not associated with response to citalopram and escitalopram in people with Depressive Disorder as compared to allele A.	no	= 0.2195	306		European	Efficacy	false	This is one of SNP showed some association with plasma serotonin concentrations and was suspected to be associated with SSRI clinical response. When tested in the PGRN-AMPS GWAS and in two independent SSRI response GWAS (STAR*D and ISPC) it was not associated with response in any cohort.	citalopram; escitalopram
982023075	rs6318	PMID:23221997	HTR2C	Allele G is not associated with remission rates when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.	no	= 0.27	159		European	Efficacy	false		citalopram
655385916	rs2032583	PMID:18215618	ABCB1	Genotypes AG + GG are associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to genotype AA.	yes	= 0.0062	359		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks but not at 5 or at 6 weeks.	amitriptyline; citalopram; paroxetine; venlafaxine
1449717828	CYP2C19 poor metabolizer phenotype	PMID:30135031	CYP2C19	CYP2C19 poor metabolizer phenotype is associated with increased response to citalopram or escitalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizer phenotype.	yes	= 0.00025	4135		European	Efficacy	false	CYP2C19 poor metabolizers had higher symptom improvement scores and higher remission rates compared to normal metabolizers. Metabolizer phenotypes were assigned based on genotyping for the *1, *2 and *17 alleles.	citalopram; escitalopram
1184512692	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:19468717	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	yes	= 0.032	362		East Asian	Efficacy	false	"For 5-HTTLPR genotyping, the homozygotes were designated as L/L (528 bp, 16
copies) or S/S (484 bp, 14 copies), and the heterozygotes designated as L/S."	citalopram; fluoxetine; paroxetine
1448112254	CYP2D6*1; CYP2D6*2; CYP2D6*10; CYP2D6*87; CYP2D6*88; CYP2D6*89; CYP2D6*90; CYP2D6*91; CYP2D6*93; CYP2D6*98	PMID:27016952	CYP2D6	CYP2D6 *2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98 are associated with decreased clearance of citalopram as compared to CYP2D6 *1.	yes	< 0.01			Unknown	Metabolism/PK	false	Variants were introduced into CYP2D6 cDNA and expressed in insect cells. The variants showed a reduced intrinsic clearance for both demethylation and oxidation of citalopram compared to *1. Note, most constructs are only including a single variant even though the star alleles are defined by a combination of variants, e.g. *87, *94, *95 are missing the 100C>T P34S variant in the construct used for the in-vitro assay and *91 is missing the 2989G>A (splicing defect) variant.	citalopram
1450931541	rs6313	PMID:30221791	HTR2A	Allele G is not associated with likelihood of Nausea and Vomiting due to citalopram and sertraline in people with Depressive Disorder, Major as compared to allele A.	no	= 0.13	65		Unknown	Toxicity	false	This variant is referred to in the paper as the 102 T/C SNP. Please note that alleles have been complemented to the positive strand.	citalopram; sertraline
981476274	rs11983225	PMID:18215618	ABCB1	Allele C is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele T.	yes	= 0.0034	257		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1183634361	rs56294817	PMID:19481584	HES6	Allele A is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele C.	no	> 0.05	278		Unknown	Efficacy	false		citalopram; fluoxetine; paroxetine
637880371	rs7997012	PMCID:PMC1474035	HTR2A	Genotype AA is associated with increased likelihood of response when treated with citalopram in people with Depression as compared to genotype GG.	yes	= 2.0E-6	1329		Multiple groups	Efficacy	false		citalopram
769169379	rs2518224	PMID:17898344	GRIK2	Genotype CC is associated with increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with Depression.	yes	< 0.003	1862		Multiple groups	Toxicity	false	In combination with the G risk allele at rs4825476 in GRIA3: OR=14.98 (3.7-60.674), and likelihood ratio test; chi squared = 12.3, p=0.0004.	citalopram
637880382	rs7997012	PMCID:PMC2896826	HTR2A	Allele A is associated with increased likelihood of response when treated with citalopram in people with Depression as compared to allele G.	yes	= 2.0E-4	1953		Multiple groups, 78% Caucasian	Efficacy	false		citalopram
1183634353	rs1374385	PMID:19481584	HES6	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.	no	> 0.05	278		Unknown	Efficacy	false		citalopram; fluoxetine; paroxetine
1183848110	rs1074145	PMCID:PMC4137829		Allele A is associated with concentrations of S-citalopram and metabolic ratio of of S-desmethylcitalopram/citalopram when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to allele G.	yes	< 0.05	435		European	Other	false	no direction are giving for the association; p = 4.1E-09 for drug concentration and p = 2.0E-16 for metabolic ratio	citalopram; escitalopram
769169383	rs4825476	PMID:17898344	GRIA3	Allele G is associated with increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with Depression.	yes	< 0.01	1862		Multiple groups	Toxicity	false	In combination with the CC risk genotype at rs2518224 in GRIK2: OR=14.98 (3.7-60.674), and likelihood ratio test; chi squared = 12.3, p=0.0004.	citalopram
1183847599	rs11628713	PMCID:PMC2819190	PAPLN	Allele T is associated with increased risk of suicidal ideation when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.	yes	= 0.01	90	90	European	Toxicity	false	P = 6.2Ã—10-7, odds ratio (OR) = 4.9, permutation P = 0.01	citalopram
1184484056	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMCID:PMC4358736	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is not associated with increased likelihood of remission when treated with citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	no	= 0.1	221		European	Efficacy	false	16-item Quick Inventory of Depressive Symptomatology-Clinician Rating (QIDS-CR16)	citalopram
1184513755	rs12054895	PMID:23377640		Allele T is associated with increased improvement over the first 2 weeks when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to allele G.	no	= 0.0000000265	1354		European	Efficacy	false	Association was only with early improvement but not with outcome of early partial response (defined as a 25% improvement on the HAM-D (or equivalent rating on the MADRS or the clinician-rated QIDS)) at 2 weeks. Association was found in a meta-analysis of 980 participants from the STAR*D study and 374 (out of 672) participants from the GENDEP study, that were treated with an SSRI (citalopram or escitalopram) but not in a meta-analysis for STAR*D, GENDEP and MARS.	citalopram; escitalopram
981476290	rs10248420	PMID:18215618	ABCB1	Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A.	yes	= 0.0095	256		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1451254722	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:19468717	SLC6A4	SLC6A4 HTTLPR long form (L allele) is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	no	= 0.617	362		East Asian	Efficacy	false		citalopram; fluoxetine; paroxetine
1184169426	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:23545896	CYP2C19	CYP2C19 *1/*1 + *1/*17 + *2/*17 is not associated with treatment response when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3.	no	= 0.939	184		Multiple groups, predominantly European ancestry (90.2%)	Efficacy	false	The association is for impact of CYP2D6 (P=0.743) or CYP2C19 (P=0.939) on overall response (defined see below). A nonsignificant trend for association of predicted CYP2C19 metabolizer status with treatment response to sertraline (P=0.064) was found but the direction of the association was not reported. Patients had undergone one or more trials of serotonin reuptake inhibitors (including fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram or escitalopram), venlafaxine, mirtazapine, duloxetine or clomipramine. articipants had multiple trials of medications, individuals were defined as an overall responder (that is, to medications in general) if they reported response to greater than or equal to50% of all drug trials recalled. Correspondingly, patients who reported benefits from <50% of medications tried were deemed overall nonresponders.	citalopram; clomipramine; duloxetine; escitalopram; fluoxetine; fluvoxamine; mirtazapine; paroxetine; sertraline; venlafaxine
1448631838	CYP2C19 normal metabolizer genotype	PMID:28470107	CYP2C19	CYP2C19 normal metabolizer genotype is not associated with likelihood of aggression when treated with citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine and Selective serotonin reuptake inhibitors in people with Anxiety Disorders and Depression.	no		18	99	Unknown	Toxicity	false	"genotypes were not significantly different between cases (aggression while on SSRIs) and heathy blood donor controls. But authors state ""However, these numbers are too small to draw any conclusion."""	citalopram; escitalopram; fluoxetine; fluvoxamine; paroxetine; Selective serotonin reuptake inhibitors
827807760	rs4713916	PMCID:PMC2587308	FKBP5	Allele A is associated with increased likelihood of remission when treated with citalopram in people with Depressive Disorder, Major as compared to allele G.	yes	= 0.013	1446	934	Multiple groups, Non hispanic white and black	Efficacy	false		citalopram
981476298	rs2235040	PMID:18215618	ABCB1	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.	yes	= 6.6E-4	269		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1448631828	CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes	PMID:28470107	CYP2D6	CYP2D6 normal metabolizer and ultra-metabolizer genotypes is not associated with likelihood of aggression when treated with citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine and Selective serotonin reuptake inhibitors in people with Anxiety Disorders and Depression.	no		18	99	Unknown	Toxicity	false	"genotypes were not significantly different between cases (aggression while on SSRIs) and heathy blood donor controls. Cases had no PMs. But authors state ""However, these numbers are too small to draw any conclusion."""	citalopram; escitalopram; fluoxetine; fluvoxamine; paroxetine; Selective serotonin reuptake inhibitors
1451116595	CYP2C19 intermediate metabolizer phenotype	PMID:31257122	CYP2C19	CYP2C19 intermediate metabolizer phenotype is associated with increased severity of Serotonin Syndrome due to citalopram in women with Depression.	no		1		Unknown	Toxicity	false	Case study of a patient admitted to the emergency department after a citalopram overdose. Patient was diagnosed with serotonin syndrome and the authors note that, based on previous experience with citalopram overdose, the duration and severity of symptoms in this patient was unusual. Patient was found to be a CYP2C19 intermediate metabolizer, although the exact genotype is not given.	citalopram
827921673	rs2032583	PMID:22641028	ABCB1	Allele G is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele A.	yes	= 4.0E-4	424		Unknown	Toxicity	false	This SNP was significant alone and as part of a haplotype of 6 ABCB1 variants.	citalopram; fluvoxamine; paroxetine; sertraline; venlafaxine
981476308	rs12720067	PMID:18215618	ABCB1	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.	yes	= 0.002	261		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1183620053	rs776746	PMCID:PMC2268970	CYP3A5	Allele C is not associated with differences in remission or tolerance when treated with citalopram in people with Depressive Disorder, Major as compared to allele T.	no		1046		Multiple groups	Efficacy,Toxicity	false		citalopram
981861603	rs7124442	PMID:19236730	BDNF	Genotype TT is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotypes CC + CT.	yes	= 0.01	268	424	European	Efficacy	false	The association was with worse treatment outcome over 6 weeks and this applied particularly to anxious depression, for which p = 0.003.	citalopram
981344274	rs915120	PMCID:PMC3941038	GRK5	Allele C is associated with decreased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to allele T.	no	= 1.15E-5	398		European	Efficacy	false	No SNP reached the genome-wide level of significance (P<10-7), although this variant was shown in functional molecular experiments to influence transcription by a reporter gene assay and to alter nuclear protein binding using an electrophoretic mobility shift assay.	citalopram; escitalopram
981477870	rs25531	PMCID:PMC2660379	SLC6A4	Allele C is not associated with response to citalopram in people with Depression as compared to allele T.	no		1074		European	Efficacy	false		citalopram
981502448	rs6966038	PMCID:PMC2794921		Allele G is associated with increased response to citalopram in people with Depressive Disorder, Major as compared to allele A.	no	= 0.2	1491		Multiple groups, African American, non-Hispanic Caucasian and Hispanic Caucasian	Efficacy	false	It was also associated with remission.  Neither association was significant after correction (430,198 SNPs tested).  Frequencies listed below are for responders vs. nonresponders.  Authors point out the lack of placebo control.	citalopram
1446908239	CYP2C19*1; CYP2C19*17	PMID:26343256	CYP2C19	CYP2C19 *1/*17 is not associated with metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	no	> 0.05	50		Unknown	Metabolism/PK	false	Plasma citalopram, desmethylcitalopram concentrations and M/R value in the CYP2C19*1/*1 genotypes were no different to those of the CYP2C19*1/*17 genotypes.	citalopram
1448276512	rs2235015	PMID:26704739	ABCB1	Genotype AA is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AC.	no	= 0.513	73		Unknown	Efficacy	false	Efficacy was measured as change in Hamilton Rating Scale for Depression (HAM-D-17). Patients were randomized to a high-dose arm and a normal-dose arm. Assessment made after 0, 7, 14, 21, and 28 days of treatment.	amitriptyline; citalopram; escitalopram; nortriptyline; paroxetine; Selective serotonin reuptake inhibitors; sertraline; trimipramine; venlafaxine
1184484076	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMCID:PMC4358736	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased likelihood of remission when treated with citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	yes	= 0.034	43		European	Efficacy	false	Only in a subset of the cohort, in patients with the first depession episode at the age of 56 and above. 16-item Quick Inventory of Depressive Symptomatology-Clinician Rating (QIDS-CR16)	citalopram
981502454	rs6127921	PMCID:PMC2794921		Allele C is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to allele A.	no	= 1.4	1491		Multiple groups, African American, non-Hispanic Caucasian and Hispanic Caucasian	Efficacy	false	It was also associated with remission.  Neither association was significant after correction (430,198 SNPs tested).  Authors point out the lack of placebo control.	citalopram
982046974	CYP2D6*1; CYP2D6*2xN	PMID:11802100	CYP2D6	CYP2D6 *1/*2xN is not associated with increased metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	no		19		European	Metabolism/PK	false		citalopram
981750780	rs6295	PMID:19590397	HTR1A	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.	no		86	395	European	Efficacy	false	This SNP was also not found to be associated with Major Depressive Disorder.	citalopram; fluoxetine; paroxetine
982046960	CYP2D6*1; CYP2D6*4	PMID:11802100	CYP2D6	CYP2D6 *1/*4 is not associated with decreased metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2D6 *1/*1.	no		19		European	Metabolism/PK	false		citalopram
1183619572	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMCID:PMC1884377	CYP2C19	CYP2C19 *2/*2 + *2/*3 are associated with increased AUC of the S-enantiomer of citalopram (no effect on R-CT) when treated with citalopram in healthy individuals as compared to CYP2C19 *1/*1.	yes	= 0.05	18		European	Metabolism/PK	false	CYP2C19*2 and *3 and CYP2D6 *3,*4, *5 were genotypes. no diplotpes reported. patients were also phenotyped with mephenytoin (Me) and debrisoquine (De). Grouped by EMDe/EMMe, PMDe/EMMe, EMDe/PMMe (n = 6 in all groups) (one PMDe/PMMe subject-excluded duo to ADR). AUC of S-CT was significantly higher in the EMDe/PMMe panel compared to the EMDe/EMMe and PMDe/EMMe panels .	citalopram
1296598832	rs520210	PMID:23809733	NEDD4L	Allele A is associated with increased response to citalopram in people with Depression as compared to allele G.	yes	= 3.64E-8	1426		Multiple groups, non-HIspanic Caucasian, African-American, Hispanic Caucasian	Efficacy	false	GWAS. Responders to antidepressant treatment had a higher frequency of the A allele as compared to non-responders. Responders were patients that showed a 50% or greater reduction, from baseline to final visit, in the self-report 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR). Participants who did not meet this criteria were non-responders. Patients had to complete at least 6 weeks of treatment with citalopram to be included.	citalopram
1450931459	rs17162912	PMID:29953682	DISP1	Allele C is not associated with response to citalopram, clomipramine, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Obsessive-Compulsive Disorder as compared to allele T.	no	> 0.05	112		European	Efficacy	false	No significant association between this variant and SRI or SSRI response using additive or dominant models. Note that this allele was not in HWE in the cohort (p=0.0008).	citalopram; clomipramine; fluoxetine; fluvoxamine; paroxetine; sertraline
981344263	rs11144870	PMCID:PMC3941038	RFK	Allele T is associated with decreased response to citalopram or escitalopram in people with Depressive Disorder, Major as compared to allele C.	no	= 1.04E-6	398		European	Efficacy	false	No SNP reached the genome-wide level of significance (P<10-7), although this variant was shown in functional molecular experiments to influence transcription by a reporter gene assay and to alter nuclear protein binding using an electrophoretic mobility shift assay.	citalopram; escitalopram
981502459	rs809736	PMCID:PMC2794921	RORA	Allele G is associated with increased response to citalopram in people with Depressive Disorder, Major as compared to allele A.	no	= 3.5	1491		Multiple groups, African American, non-Hispanic Caucasian and Hispanic Caucasian	Efficacy	false	It was also associated with remission.  Neither association was significant after correction (430,198 SNPs tested).  Frequencies listed below are for responders vs. nonresponders.  Authors point out the lack of placebo control.	citalopram
1184484066	rs25531	PMCID:PMC4358736	SLC6A4	Allele C is not associated with increased likelihood of remission when treated with citalopram in people with Depressive Disorder, Major as compared to allele T.	no	= 0.92	221		European	Efficacy	false	16-item Quick Inventory of Depressive Symptomatology-Clinician Rating (QIDS-CR16)	citalopram
1451407100	rs6265	PMID:31792367	BDNF; BDNF-AS	Allele T is not associated with likelihood of Sexual Dysfunctions, Psychological due to citalopram or sertraline in people with Depressive Disorder, Major as compared to allele C.	no		133		Unknown	Toxicity	false		citalopram; sertraline
1184484070	rs57098334	PMCID:PMC4358736		Allele (CCCACCCGA)12 is not associated with increased likelihood of remission when treated with citalopram in people with Depressive Disorder, Major as compared to allele (CCCACCCGA)9.	no	= 0.46	221		European	Efficacy	false	16-item Quick Inventory of Depressive Symptomatology-Clinician Rating (QIDS-CR16)	citalopram
981501697	rs9380524	PMCID:PMC3784025	FKBP5	Allele A is associated with poor response after 8 weeks of treatment when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to allele C.	no	= 0.0175	512		European	Efficacy	false	associations were not significant after correction for multiple testing	citalopram; escitalopram
1183619342	CYP2C19*1; CYP2C19*4	PMCID:PMC3090085	CYP2C19	CYP2C19 *4 is associated with increased intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	not stated	= 0.06	952		European	Toxicity	false	The study grouped all loss-of-function alleles found in study (*2,*4,*6,*8), therefore not only *4. Trend of association was reported p=0.06. *17 was also genotyped, no information given for *17.	citalopram
1448276439	rs2032583	PMID:26704739	ABCB1	Genotype GG is not associated with response to amitriptyline, citalopram, escitalopram, nortriptyline, paroxetine, Selective serotonin reuptake inhibitors, sertraline, trimipramine or venlafaxine in people with Bipolar Disorder as compared to genotypes AA + AG.	no	= 0.442	73		Unknown	Efficacy	false	Efficacy was measured as change in Hamilton Rating Scale for Depression (HAM-D-17). Patients were randomized to a high-dose arm and a normal-dose arm. Assessment made after 0, 7, 14, 21, and 28 days of treatment.	amitriptyline; citalopram; escitalopram; nortriptyline; paroxetine; Selective serotonin reuptake inhibitors; sertraline; trimipramine; venlafaxine
981750786	rs6313	PMID:19590397	HTR2A	Allele A is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.	no		86	395	European	Efficacy	false	This SNP was also not found to be associated with Major Depressive Disorder.	citalopram; fluoxetine; paroxetine
1184748315	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:25154506	CYP2C19	CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 is associated with increased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	yes	< 0.05	847		Multiple groups, Asian and White	Metabolism/PK	false	Compared to subjects with the EM/EM (CYP2C19*1/*1) genotype, the exposure to (es)citalopram increased by 30 % (95 % CI 4-55, p < 0.05) in EM/PM (CYP2C19*1/*2 or *3), and 25 % (95 % CI 1-49, p < 0.05) in UM/PM (CYP2C19*17/*2 or *3) groups. For this meta-analysis of 16 studies (in Asian and White), the studies must meet the following criteria to be included: (1) all subjects received at least one single dose of citalopram or escitalopram orally; (2) either genotyping or phenotyping of CYP2C19 was performed in all subjects; (3) citalopram or escitalopram exposure level [mean and standard deviation (SD)] was presented separately for the EM/EM genotype group and at least one of the following groups: UM/UM, UM/EM, UM/PM, EM/PM, PM/PM; and (4) if polymorphism was only assessed by phenotyping, citalopram or escitalopram exposure was reported separately for the EMpheno and PMpheno groups.	citalopram; escitalopram
981861633	rs7103411	PMID:19236730	BDNF	Genotype TT is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype CC.	yes	= 0.003	268	424	European	Efficacy	false	The association was with worse treatment outcome over 6 weeks only in clinical subtypes such as melancholic depression.	citalopram
769164370	rs10975641	PMCID:PMC3034442	GLDC	Allele G is associated with increased response to citalopram and escitalopram in people with Depressive Disorder, Major as compared to allele C.	yes	= 0.016	1245		European	Efficacy	false	"Be careful- GC SNP.  The paper states that the minor allele was assoc with decreased odds for remission(in the original cohort), and from dbSNP freq/orientation of fastA compared to Golden path, I believe G on the + chr strand to be the minor allele.  For the STAR*D study, remission was not found to be significantly associated; the significant association was with ""the binary phenotype ""response""""."	citalopram; escitalopram
981501708	rs352428	PMCID:PMC3784025		Allele A is associated with poor response at 8 week of treatment when treated with citalopram or escitalopram in people with Depressive Disorder, Major as compared to allele G.	yes	= 0.003	512		European	Efficacy	false		citalopram; escitalopram
982046981	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:11802100	CYP2C19	CYP2C19 *1/*2 is not associated with decreased metabolism of citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	no		19		European	Metabolism/PK	false		citalopram
982029829	rs4244285	PMID:20531370	CYP2C19	Genotype AA is associated with increased metabolic ratio CIT/DCIT values and mean citalopram dose when treated with citalopram as compared to genotype GG.	yes	< 0.05	338		Unknown	Metabolism/PK	false		citalopram
981750795	rs6311	PMID:19590397	HTR2A	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele T.	no		86	395	European	Efficacy	false	This SNP was also not found to be associated with Major Depressive Disorder.	citalopram; fluoxetine; paroxetine
1184169499	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMID:23545896	CYP2C19	CYP2C19 *1/*1 + *1/*17 + *2/*17 is not associated with side effects when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder as compared to CYP2C19 *1/*2 + *1/*3 + *2/*2 + *2/*3.	no	= 0.391	184		Multiple groups, predominantly European ancestry (90.2%)	Toxicity	false	The association is for impact of CYP2D6 (P=0.619) or CYP2C19 (P=0.391) on the occurrence of significant side effects in all trials overall (defined see below). Patients had undergone one or more trials of serotonin reuptake inhibitors (including fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram or escitalopram), venlafaxine, mirtazapine, duloxetine or clomipramine. articipants had multiple trials of medications, individuals were defined as an overall responder (that is, to medications in general) if they reported response to greater than or equal to50% of all drug trials recalled. Correspondingly, patients who reported benefits from <50% of medications tried were deemed overall nonresponders. A similar approach was taken for side effects.	citalopram; clomipramine; duloxetine; escitalopram; fluoxetine; fluvoxamine; mirtazapine; paroxetine; sertraline; venlafaxine
1184503573	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:23510446	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased response to citalopram in children with Depressive Disorder as compared to SLC6A4 HTTLPR short form (S allele).	no	= 0.03	83		Unknown	Efficacy	true	Response was defined as  response (Clinical Global Impressions - Improvement </=2). Association was non-significant following Bonferroni correction. 5-HTTLPR was amplified, and the two amplification products (528bp and 484bp for the long and short alleles respectively) were separated on 2% agarose gel.	citalopram
981502225	rs495794	PMID:22795047	SRP19	Allele G is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele A.	yes	= 0.017	165		East Asian	Efficacy	false	"Response to the four antidepressants was measured by the Hamilton Rating Scale for Depression (HAMD). ""Responders"" were defined as patients with at least a 50% reduction in HAMD total score after 6 weeks of treatment. The G allele was significantly more frequent in responders than in non-responders. Additionally, carriers of the G allele had a greater reduction in HAMD scores after 6 weeks of treatment than carriers of the A allele."	citalopram; fluoxetine; paroxetine; sertraline
1183620125	rs1045642	PMCID:PMC2268970	ABCB1	Allele G is not associated with differences in remission or tolerance when treated with citalopram in people with Depressive Disorder, Major as compared to allele A.	no		1046		Multiple groups	Efficacy,Toxicity	false		citalopram
981501714	rs352428	PMCID:PMC3784025		Allele A is associated with poor response at 6 week of treatment when treated with citalopram in people with Depressive Disorder, Major as compared to allele G.	yes	= 0.05	960		European	Efficacy	false		citalopram
1183619358	CYP2D6*1; CYP2D6*4	PMCID:PMC3090085	CYP2D6	CYP2D6 *4 is not associated with increased risk of intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2D6 *1.	no		952		European	Toxicity	false	CYP2D6 genotype-based categories, therefore not only *4, were not found to be significantly associated with tolerance. Detailed results were not shown in study. Alleles found in study  (*2, *3, *4, *5, *6, *7, *9, *10, *17, *41 and duplications).	citalopram
1184137222	CYP2C19*2	PMID:15168101	CYP2C19	CYP2C19 *2/*2 (assigned as poor metabolizers phenotype) is associated with plasma concentrations when treated with citalopram in people with Depressive Disorder, Major.	no		1		European	Metabolism/PK	false	Association with 64% greater citalopram concentrations (n=1) vs median dose-corrected plasma concentrations. Multi drug study only one patient CYP2C19 PM; PM defined as carrying two non functional alleles; Only *2 was genotype in study cohort.	citalopram
699642407	rs4675690	PMID:17548750		Allele T is associated with increased likelihood of treatment-emergent suicidality when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.	yes	= 0.005	124	1324	Multiple groups, 79% white	Toxicity	false		citalopram
981750801	rs7997012	PMID:19590397	HTR2A	Allele A is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.	no		86	395	European	Efficacy	false	This SNP was also not found to be associated with Major Depressive Disorder.	citalopram; fluoxetine; paroxetine
699642404	rs7569963	PMID:17548750	CREB1; METTL21A	Allele A is associated with decreased likelihood of treatment-emergent suicidality when treated with citalopram in people with Depressive Disorder, Major as compared to allele G.	yes	= 0.005	124	1324	Multiple groups, 79% white	Toxicity	false		citalopram
981502232	rs153549	PMID:22795047	REEP5	Allele A is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	yes	= 0.0089	165		East Asian	Efficacy	false	"Response to the four antidepressants was measured by the Hamilton Rating Scale for Depression (HAMD). ""Responders"" were defined as patients with at least a 50% reduction in HAMD total score after 6 weeks of treatment. The A allele was significantly more frequent in responders than in non-responders. Additionally, carriers of the A allele had a greater reduction in HAMD scores after 6 weeks of treatment than carriers of the G allele."	citalopram; fluoxetine; paroxetine; sertraline
982029840	rs12248560	PMID:20531370	CYP2C19	Genotype TT is associated with decreased metabolic ratio CIT/DCIT values when treated with citalopram as compared to genotype CC.	yes	< 0.05	338		Unknown	Metabolism/PK	false		citalopram
1183619350	CYP2C19*1; CYP2C19*2	PMCID:PMC3090085	CYP2C19	CYP2C19 *2 is associated with increased intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	yes	= 0.02	952		European	Toxicity	false		citalopram
1184137230	CYP2C19*1; CYP2C19*2	PMID:20531370	CYP2C19	CYP2C19 *2/*2 is associated with increased metabolic ratio CIT/DCIT values and mean citalopram dose when treated with citalopram as compared to CYP2C19 *1/*1.	yes	< 0.05	338		Unknown	Metabolism/PK	false		citalopram
981750815	rs1800532	PMID:19590397	TPH1	Allele T is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele G.	no		86	395	European	Efficacy	false	This SNP was also not found to be associated with Major Depressive Disorder.	citalopram; fluoxetine; paroxetine
981750809	rs1805054	PMID:19590397	HTR6	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele T.	no		86	395	European	Efficacy	false	This SNP was also not found to be associated with Major Depressive Disorder.	citalopram; fluoxetine; paroxetine
655386253	rs2235015	PMID:18215618	ABCB1	Allele A is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.	yes	= 0.025	339		European	Efficacy	false	Association was significant after correction for multiple testing at 6 weeks, but not so at 4 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
981502239	rs153560	PMID:22795047	REEP5	Allele G is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele A.	yes	= 0.0036	165		East Asian	Efficacy	false	"Response to the four antidepressants was measured by the Hamilton Rating Scale for Depression (HAMD). ""Responders"" were defined as patients with at least a 50% reduction in HAMD total score after 6 weeks of treatment. The G allele was significantly more frequent in responders than in non-responders. Additionally, carriers of the G allele had a greater reduction in HAMD scores after 6 weeks of treatment than carriers of the A allele."	citalopram; fluoxetine; paroxetine; sertraline
981861657	rs6265	PMID:19236730	BDNF	Genotype CC is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype TT.	yes	= 0.001	268	424	European	Efficacy	false	The association was with worse treatment outcome over 6 weeks only in clinical subtypes such as melancholic depression.	citalopram
1183689490	rs28401781	PMID:24192121	ABCB1	Allele T is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.	no	= 0.267	284		East Asian	Efficacy	false	Allele T was more frequent in the responders group. This association did not remain statistically significant after correction for false-discovery rate and genotypes were not significantly associated. Please note; alleles have been complemented to the plus chromosomal strand. This SNP was in strong LD with rs4148739.	citalopram; fluoxetine; paroxetine; sertraline
827921657	rs2235040	PMID:22641028	ABCB1	Allele T is associated with increased likelihood of adverse effects when treated with citalopram, fluvoxamine, paroxetine, sertraline or venlafaxine in people with Depressive Disorder, Major as compared to allele C.	yes	= 4.0E-4	424		Unknown	Toxicity	false	This SNP was significant alone and as part of a haplotype of 6 ABCB1 variants.	citalopram; fluvoxamine; paroxetine; sertraline; venlafaxine
1184137268	CYP2D6 poor metabolizers	PMCID:PMC1884377	CYP2D6	CYP2D6 poor metabolizers is associated with increased risk of severe adverse effects when treated with citalopram in healthy individuals.	no		1		European	Toxicity	false	Association with stopping citalopram after five days due to severe adverse effects in combination with CYP2C19 PM. Subject was a poor metabolizer for CYP2C19 and CYP2D6.	citalopram
637880231	rs1954787	PMID:17671280	GRIK4	Allele C is associated with decreased likelihood of non-response when treated with citalopram in people with Depression as compared to allele T.	yes	= 0.00384	1199		Multiple groups	Efficacy	false		citalopram
981750822	rs1386494	PMID:19590397	TPH2	Allele C is not associated with response to citalopram, fluoxetine or paroxetine in people with Depressive Disorder, Major as compared to allele T.	no		86	395	European	Efficacy	false	This SNP was also not found to be associated with Major Depressive Disorder.	citalopram; fluoxetine; paroxetine
769171579	rs334558	PMID:18195729	GSK3B	Genotype GG is associated with increased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.	yes	= 0.002	168		East Asian	Efficacy	false		citalopram; fluoxetine
1183620143	rs2740574	PMCID:PMC2268970	CYP3A4	Allele T is not associated with differences in remission or tolerance when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.	no		1046		Multiple groups	Efficacy,Toxicity	false		citalopram
1183620136	rs2032582	PMCID:PMC2268970	ABCB1	Allele C is not associated with differences in remission or tolerance when treated with citalopram in people with Depressive Disorder, Major as compared to allele A.	no		1046		Multiple groups	Efficacy,Toxicity	false		citalopram
1183619369	CYP2C19*1; CYP2C19*2	PMCID:PMC3090085	CYP2C19	CYP2C19 *2 is not associated with remission when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1.	no		952		European	Efficacy	false	Study found *2,*4,*6,*8 and *17. CYP2C19 genotype-based groups did not show overall evidence of association with remission, therefore not only *2 compared to *1.	citalopram
1184513852	SLC6A4 HTTLPR short form (S allele); SLC6A4 L allele-rs25531C; SLC6A4 L allele-rs25531T	PMID:17606812	SLC6A4	SLC6A4 L allele-rs25531T/L allele-rs25531T is associated with decreased adverse effect burden when treated with citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele)/L allele-rs25531C.	yes	= 0.03	1131		European	Toxicity	false	Adverse effects were evaluated using the patient-rated Global Rating of Side Effect Burden (GRSEB) score. Association was not significant if L and S allele were compared.	citalopram
1451407140	rs6311	PMID:31792367	HTR2A	Allele T is associated with increased likelihood of Sexual Dysfunctions, Psychological due to citalopram or sertraline in people with Depressive Disorder, Major as compared to allele C.	yes	= 0.02	67		Unknown	Toxicity	false	Please note that alleles have been complemented to the positive strand.	citalopram; sertraline
1183619883	CYP2C19*1; CYP2C19*2	PMID:16855453	CYP2C19	CYP2C19 *2 is associated with decreased citalopram oral clearances of citalopram when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	yes	= 0.05	53		East Asian	Metabolism/PK	false	oral clearances in the PMs were 42.9% and 33.3% (both P < 0.05) lower compared with the homozygous and heterozygous EMs.	citalopram
1183701546	CYP2D6*1; CYP2D6*10	PMID:23981149	CYP2D6	CYP2D6 *1/*10 + *10/*10 is associated with decreased clearance of citalopram in healthy individuals as compared to CYP2D6 *1/*1.	yes	= 0.036	23		East Asian	Metabolism/PK	false	"CYP2D19*2 and *3; CYP2D6*10. 9 subjects *1/*1 and 14 subjects *1/*2
subjects for CYP2C19. 4 *1/*1, 7 *1/*10 and 12 *10/*10 subjects for
CYP2D6."	citalopram
1183701537	CYP2C19*1; CYP2C19*2	PMID:23981149	CYP2C19	CYP2C19 *1/*2 is not associated with clearance of citalopram in healthy individuals as compared to CYP2C19 *1/*1.	no	= 0.071	23		East Asian	Metabolism/PK	false	As trend the CL/F of CYP2C19 *1/*1 subjects is higher than that of *1/*2 subjects. Genotyped for CYP2D19*2 and *3; CYP2D6*10. 9 subjects *1/*1 and 14 subjects *1/*2 subjects for CYP2C19.	citalopram
1184748337	CYP2C19*1; CYP2C19*17	PMID:25154506	CYP2C19	CYP2C19 *1/*17 is associated with decreased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	yes	< 0.05	847		Multiple groups, Asian and White	Metabolism/PK	false	Compared to subjects with the EM/EM (CYP2C19*1/*1) genotype, the exposure to (es)citalopram decreased by 14 % (95 % CI 1-27, p < 0.05) in the UM/EM (CYP2C19*17/*1) group. For this meta-analysis of 16 studies (in Asian and White), the studies must meet the following criteria to be included: (1) all subjects received at least one single dose of citalopram or escitalopram orally; (2) either genotyping or phenotyping of CYP2C19 was performed in all subjects; (3) citalopram or escitalopram exposure level [mean and standard deviation (SD)] was presented separately for the EM/EM genotype group and at least one of the following groups: UM/UM, UM/EM, UM/PM, EM/PM, PM/PM; and (4) if polymorphism was only assessed by phenotyping, citalopram or escitalopram exposure was reported separately for the EMpheno and PMpheno groups.	citalopram; escitalopram
1183620131	rs1128503	PMCID:PMC2268970	ABCB1	Allele G is not associated with differences in remission or tolerance when treated with citalopram in people with Depressive Disorder, Major as compared to allele A.	no		1046		Multiple groups	Efficacy,Toxicity	false		citalopram
981848117	rs17135437	PMCID:PMC3410623	COL26A1	Allele T is associated with increased hearing and vision-related side-effects when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.	yes	= 3.27E-8	1762		Multiple groups	Toxicity	false	The T allele is associated with an increased incidence of ringing in the ears and blurred vision. Side effects were rated on the Patient-Rated Inventory of Side Effects (PRISE). Patients either indicated that the side effect was present or it was not. Please note these alleles have been complemented to the plus chromosomal strand.	citalopram
1450415299	CYP2C19*1; CYP2C19*2	PMID:30983508	CYP2C19	CYP2C19 *1/*2 is not associated with increased likelihood of Acquired Long QT Syndrome (aLQTS) when treated with citalopram, escitalopram or sertraline in people with Cardiovascular Diseases and Depression as compared to CYP2C19 *1/*1.	no	= 0.995	58	136	Unknown	Toxicity	false	For poor metabolizers exposed to sertraline, citalopram or escitalopram, providers changed prescribing patterns in response to alerts in the electronic medical record by either changing the drug, changing the dose or monitoring serial EKGs longitudinally. For intermediate metabolizers exposed to sertraline, citalopram or escitalopram, no alert was needed as no difference in QT was observed.	citalopram; escitalopram; sertraline
1451407152	rs6313	PMID:31792367	HTR2A	Genotype AA is associated with increased likelihood of Sexual Dysfunctions, Psychological due to citalopram in people with Depressive Disorder, Major as compared to genotypes AG + GG.	yes	= 0.02	66		Unknown	Toxicity	false	Please note that alleles have been complemented to the positive strand.	citalopram
1183689534	rs1109866	PMID:24192121	ABCB6	Allele T is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.	no	= 0.386	276		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1183619391	CYP2D6*1; CYP2D6*4	PMCID:PMC3090085	CYP2D6	CYP2D6 *4 is not associated with differences in remission when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2D6 *1.	no		952		European	Efficacy	false	CYP2D6 genotype-based categories, therefore not only *4, were not found to be significantly associated with remission. Detailed results were not shown in study. Alleles found in study  (*2, *3, *4, *5, *6, *7, *9, *10, *17, *41 and duplications).	citalopram
1183689529	rs4148739	PMID:24192121	ABCB1	Allele C is associated with increased response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele T.	no	= 0.162	276		East Asian	Efficacy	false	Allele C was more frequent in the responders group. This association did not remain statistically significant after correction for false-discovery rate and genotypes were not significantly associated. Please note; alleles have been complemented to the plus chromosomal strand. This SNP was in strong LD with rs28401781.	citalopram; fluoxetine; paroxetine; sertraline
1184748329	CYP2C19*1; CYP2C19*17	PMID:25154506	CYP2C19	CYP2C19 *17/*17 (assigned as ultrarapid metabolizer phenotype) is associated with decreased exposure to citalopram or escitalopram as compared to CYP2C19 *1/*1 (assigned as normal metabolizers phenotype) .	yes	< 0.0001	847		Multiple groups, Asian and White	Metabolism/PK	false	Compared to subjects with the EM/EM (CYP2C19*1/*1) genotype, the exposure to (es)citalopram decreased by 36 % (95 % CI 27-46, p < 0.0001) in the UM/UM (CYP2C19*17/*17) group. For this meta-analysis of 16 studies (in Asian and White), the studies must meet the following criteria to be included: (1) all subjects received at least one single dose of citalopram or escitalopram orally; (2) either genotyping or phenotyping of CYP2C19 was performed in all subjects; (3) citalopram or escitalopram exposure level [mean and standard deviation (SD)] was presented separately for the EM/EM genotype group and at least one of the following groups: UM/UM, UM/EM, UM/PM, EM/PM, PM/PM; and (4) if polymorphism was only assessed by phenotyping, citalopram or escitalopram exposure was reported separately for the EMpheno and PMpheno groups.	citalopram; escitalopram
1183619898	CYP2C19*1; CYP2C19*3	PMID:16855453	CYP2C19	CYP2C19 *3 is associated with decreased citalopram oral clearances of citalopram when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	yes	= 0.01	53		East Asian	Metabolism/PK	false	oral clearances in the PMs were 42.9% and 33.3% (both P < 0.05) lower compared with the homozygous and heterozygous EMs.	citalopram
1184137250	CYP2C19*1; CYP2C19*17	PMID:20531370	CYP2C19	CYP2C19 *1/*17 is associated with decreased metabolic ratio CIT/DCIT values when treated with citalopram as compared to CYP2C19 *1/*1.	yes	< 0.05	338		Unknown	Metabolism/PK	false		citalopram
1183920937	CYP2D6*3; CYP2D6*4	PMID:22775532	CYP2D6	CYP2D6 *3/*4 (assigned as poor metabolizer phenotype) is not associated with differences in treatment response when treated with citalopram, fluoxetine, fluvoxamine, paroxetine or sertraline in people with Obsessive-Compulsive Disorder as compared to CYP2D6 normal metabolizer.	no	> 0.05	39		Unknown	Efficacy	false	CYP2D6 metabolizer status had no significant effect on clinical response (p>0.05).32 patients were CYP2D6 EMs, 2 were UMs, 4 were IMs, and 1 patient was a PM. Exploratory association analysis of response to all 108 drug trials found a significant effect of CYP2D6 metabolizer status on response (Fisher's exact test: p=0.021) when comparing the patients with reduced CYP2D6 activity (IMs and PMs) to EMs or UMs, but no information regarding the direction of the association is given. AmpliChip CYP450 test, which detects up to 33 alleles, including 7 duplications in the CYP2D6 and 3 alleles in the CYP2C19 gene. PM, IM, EM, or UM status for CYP2D6 and PM or EM status for CYP2C19 using phenotyping software available with the AmpliChip CYP450 test.	citalopram; fluoxetine; fluvoxamine; paroxetine; sertraline
1184748582	CYP2C19 poor metabolizers	PMID:25122046	CYP2C19	CYP2C19 poor metabolizers is associated with increased risk of electrocardiogram qt prolonged when treated with citalopram as compared to CYP2C19 normal metabolizers.	not stated		75		Unknown	Toxicity	false	"Study found that CYP2C19 PM(n=1) combined with IM (n=16) (440.1 Â± 26.6 ms) had longer QTc interval compared to EM (n=58) (427.1 Â± 23.6 ms) (one-tailed t-test, p=0.029). The results is driven by the PM who had a prolonged QTc. When comparing only the IM and EM groups, with the PM excluded,
there was no significant association between QTc and CYP2C19 variation, although there is still a trend for CYP2C19 EMs to have a shorter QTc than IMs (427.1 Â± 23.6 ms vs. 437.4 Â± 25.1 ms, one-tailed t-test, p=0.066). Identified genotypes or alleles are not reported."	citalopram
1448423400	CYP2C19*17	PMID:27804107	CYP2C19	CYP2C19 *17/*17 is associated with decreased response to citalopram in people with Obsessive-Compulsive Disorder.	not stated		1		Unknown	Efficacy	false	Case study. A subject genotyped as CYP2C19*17/*17 reported that citalopram was not effective for management of obsessive-compulsive disorder symptoms and increased number of panic attacks. After diplotype was determined patient was switched to paroxetine, which resulted in a reduction in both the obsessive-compulsive disorder symptoms and the intensity and frequency of the panic attacks.	citalopram
1183619378	CYP2C19*1; CYP2C19*17	PMCID:PMC3090085	CYP2C19	CYP2C19 *17 is associated with decreased remission (reported as trend of association) when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	no	= 0.1	952		European	Efficacy	false	A trend suggesting that the number of *17 alleles is associated with lower remission rates (P=0.1, OR=0.84, CI: 0.69 - 1.04). The association got stronger when restricted for patients that were classified as treatment tolerant P=0.05, OR=0.80, CI: 0.63 -1.00.	citalopram
1184169557	CYP2D6 normal metabolizers	PMID:23545896	CYP2D6	CYP2D6 normal metabolizers are associated with decreased number of failed medication trails when treated with citalopram, clomipramine, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline or venlafaxine in people with Obsessive-Compulsive Disorder.	yes	= 0.007	184		Multiple groups, predominantly European ancestry (90.2%)	Efficacy	false	Study observed that UM and PM both had undergone more medication trials than those with EM status (UM: median 3.5 trials (range 1-8), PM: median 5; EM: median 2 (range 1-9), IM: median 2 (range 1-7)). Significantly more non-EM than EM had undergone four or more drug trials (non-EM: 13/27 (48%) patients withgreater than or equal to4 trials; EM: 34/157 (22%) patients with greater than or equal to4 trials; P=0.007). Patients had undergone one or more trials of serotonin reuptake inhibitors (including fluoxetine, sertraline, fluvoxamine, paroxetine, citalopram or escitalopram), venlafaxine, mirtazapine, duloxetine or clomipramine. articipants had multiple trials of medications, individuals were defined as an overall responder (that is, to medications in general) if they reported response to greater than or equal to50% of all drug trials recalled. Correspondingly, patients who reported benefits from <50% of medications tried were deemed overall nonresponders.	citalopram; clomipramine; duloxetine; escitalopram; fluoxetine; fluvoxamine; mirtazapine; paroxetine; sertraline; venlafaxine
655386834	rs2227631	PMID:18794724	SERPINE1	Allele G is associated with decreased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.	yes	= 0.014	140		East Asian	Efficacy	false	(as haplotype with rs1799889-G)	citalopram; fluoxetine
981480002	rs6313	PMCID:PMC3582836	HTR2A	Genotype AA is associated with decreased risk of heart palpitations when treated with citalopram in people with Depression as compared to genotype GG.	yes	= 0.012	1222		Multiple groups	Toxicity	false	19.4% incidence vs. 25.1%	citalopram
1183689550	rs6946119	PMID:24192121		Allele T is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C.	no	= 0.501	215		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1183619913	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:16855453	CYP2C19	CYP2C19 *2/*2 + *2/*3 are not associated with increased Side Effects Scale scores when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.	no	= 0.234	53		East Asian	Metabolism/PK	false	TSES score also tended to be higher in PM than EM patients, but the difference was not statistically significant (P = 0.234)	citalopram
981848128	rs16965962	PMCID:PMC3410623		Allele A is associated with increased general side-effect burden when treated with citalopram in people with Depressive Disorder, Major as compared to allele C.	yes	= 3.22E-7	1762		Multiple groups	Toxicity	false	General side effect burden included 26 symptom measures across gastrointestinal, heart, skin, central nervous, vision/hearing, genital/urinary, sleep and sexual systems. Please see the paper for more details on factors included in general side effects. Also note alleles have been complemented to the plus chromosomal strand.	citalopram
1183689546	rs3755047	PMID:24192121	ABCB6	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	no	= 0.267	282		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
981865038	rs10848635	PMID:19388002	CACNA1C	Allele A is associated with increased risk of suicide when treated with citalopram in people with Depressive Disorder, Major as compared to allele T.	no	= 0.094	1167		European	Efficacy,Toxicity	false	"p is not significant after correction for testing of two SNPs.  Also, uncorrected p listed in abstract = 0.04, but in table II it is listed as 0.047 (corrected p = 0.08-0.094).  Also, it is not absolutely clear which is the associated allele, since this is an A/T SNP.  The associated allele is listed as ""the minor allele (A)"", and the gene is on the positive chromosomal strand, so probably listing A as the associated allele with respect to the positive chromosomal strand is correct.  Number genotyped is at least 1167(1206 were successfully typed for at least one locus and 1167 were successfully typed for both)."	citalopram
1183624260	CYP2D6*1xN; CYP2D6*2xN	PMID:14652703	CYP2D6	CYP2D6 *1xN + *2xN are associated with decreased response to citalopram, mianserin, mirtazapine, nortriptyline, paroxetine or venlafaxine in people with Mood Disorders.	yes	= 0.026	108		European	Efficacy	false	"The significant finding was that the worst week scores of the Hamilton Depression Rating Scale were higher in patients with the duplication compared to those without the duplication (genotyping was also done for *2, *3,*4,*5).  8/81(9.9%, 95% CI 3.4-16.4%) non-responders had a CYP2D6 gene duplication, as compared to 0.8-1.0% previously reported in healthy Nordic Caucasians. The subcohort of 81 had failed to respond to antidepressants shown to be metabolized by CYP2D6. Six UMs carried the *1/*1 xN or *1/*2 xN genotype.; For the statistics, subjects with duplication of either *1 or *2 were grouped together.  Two of the 8 subjects are listed with the duplicated allele as being in either *1 or *4, with the allele carrying the duplication not clarified.  Authors list study limitations as 1) all cases and no controls; 2) drug monitoring and CYP2D6 activity phenotyping was not done; 3) small sample size. The frequency of the EM
genotype was 0.889; the PM genotype (*3/*4, *4/*4, or *4/*5) was 0.028; and the genotype with the duplication.
was 0.083."	citalopram; mianserin; mirtazapine; nortriptyline; paroxetine; venlafaxine
1183689542	rs3731885	PMID:24192121	ABCB6	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	no	= 0.345	281		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
981480012	rs585719	PMCID:PMC3582836		Genotype CT is associated with increased response to citalopram in people with Depression as compared to genotype CC.	yes	= 0.021	156		African American/Afro-Caribbean	Efficacy	false	This was only true in African Americans and was attributed to LD with rs76665058.  No TT were seen in this cohort.	citalopram
981501261	rs25531	PMCID:PMC2887732	SLC6A4	Allele C is associated with increased likelihood of side effects when treated with citalopram in people with Dementia as compared to allele T.	yes	< 0.05	44		Multiple groups	Toxicity	false	This association is for a haplotype containing the L (long) allele at rs4795541 along with C at this SNP.	citalopram
1183689538	rs1109867	PMID:24192121	ABCB6	Allele T is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	no	= 0.384	283		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1184472392	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMID:14624186	SLC6A4	SLC6A4 HTTLPR short form (S allele)/HTTLPR short form (S allele) is associated with increased risk of non-remission when treated with citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele).	yes	= 0.006	130		Unknown	Efficacy	false	Citalopram treatment: mean initial dose: 26.4; range:20-40 mg/day. Genotyped using PCR and length determination via gel. Remission (HDRS <= 7) or in Non Remission (HDRS > 7) taking into account the HDRS scores at twelfth week.  91 patients (69.4%) were in Remission and 40 patients (30.6%) in Non-Remission.	citalopram
1183701599	CYP2C19 poor metabolizer	PMID:8451774	CYP2C19	CYP2C19 poor metabolizer is associated with decreased clearance of citalopram in healthy individuals as compared to CYP2C19 normal metabolizer.	not stated	< 0.0008	16		European	Metabolism/PK	false	Citalopram elimination partially depends on the mephenytoin oxygenase (CYP2C19), since steady-state serum concentration, half-life, and area under the serum concentration/time curve for citalopram were significantly higher in poor metabolizers	citalopram
1184168775	SLC6A4 HTTLPR short form (S allele); SLC6A4 L allele-rs25531C; SLC6A4 L allele-rs25531T	PMCID:PMC2887732	SLC6A4	SLC6A4 HTTLPR short form (S allele)/L allele-rs25531C is associated with increased likelihood of side effects when treated with citalopram in people with Dementia as compared to SLC6A4 L allele-rs25531T.	yes	< 0.05	44		Multiple groups	Toxicity	false	This was reported as the S(short) allele predicting greater early and overall side effects and early treatment discontinuation.  It is not clear which version of the S allele is meant.	citalopram
1183689563	rs182694	PMID:24192121	ABCG1	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	no	= 0.642	278		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
1184505152	rs4570625	PMID:23510446	TPH2	Genotypes GT + TT is associated with increased response to citalopram in children with Depressive Disorder as compared to genotype GG.	no	> 0.05	83		Unknown	Efficacy	true	Response was defined as  response (Clinical Global Impressions - Improvement </=2). Association was non-significant.	citalopram
1184137288	CYP2C19 poor metabolizers	PMCID:PMC3090085	CYP2C19	CYP2C19 poor metabolizers is associated with increased likelihood of remission if tolerant to citalopram treatment when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.	yes	= 0.03	896		European	Efficacy	false	CYP2C19 PM patients classified as citalopram tolerant were more likely to experience remission (P = 0.03). The study grouped all loss-of-function alleles found in study (*2,*4,*6,*8).	citalopram
1183689554	rs3747802	PMID:24192121	ABCB1	Allele A is not associated with response to citalopram, fluoxetine, paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele G.	no	= 0.542	277		East Asian	Efficacy	false	No significant differences were seen in allele or genotype frequencies between responders and non-responders.	citalopram; fluoxetine; paroxetine; sertraline
769154620	rs4244285	PMCID:PMC3090085	CYP2C19	Allele A is associated with increased intolerance when treated with citalopram in people with Depressive Disorder, Major as compared to allele G.	yes	= 0.02	952		European	Toxicity	false		citalopram
982023021	rs1800532	PMID:23221997	TPH1	Genotypes GT + TT are associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype GG.	yes	< 0.01	159		European	Efficacy	false	This association with worse treatment outcome is only significant associated in patients with major depression clinical features psychotic (F(6, 378) = 2.90; p = 0.009) and melancholic (F(6, 381) = 2.86; p = 0.0097).	citalopram
1184513661	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMCID:PMC2660379	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is not associated with remission when treated with citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	no	= 0.533	196		Latino	Efficacy	false	Remission was defined as a score of </= 5 on the 16-item Quick Inventory of Depressive Symptomatology-Clinician Rating (QIDS-C16) scale at the last clinic visit.	citalopram
1183619684	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:12975335	CYP2C19	CYP2C19 *2/*2 + *2/*3 is associated with decreased oral clearance of citalopram when treated with citalopram in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	yes		13		East Asian	Metabolism/PK	false	"Eight extensive metabolizers (genotyped as CYP2C19*1/*1, CYP2C19*1/*2, or
CYP2C19*1/*3) and five poor metabolizers (genotyped as CYP2C19*2/*2 or
CYP2C19*2/*3) were randomly selected for participation in the study. p-value not given"	citalopram
981500777	rs4713916	PMID:20709156	FKBP5	Allele A is associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele G.	yes	= 0.01	1944	908	Multiple groups	Efficacy	false	"One of the studies included in this meta-analysis was a ""Naturalistic pharmacogenetic study""."	citalopram; fluoxetine; mirtazapine; paroxetine; Selective serotonin reuptake inhibitors; venlafaxine
981865068	rs1006737	PMID:19388002	CACNA1C	Allele A is associated with increased risk of suicide when treated with citalopram in people with Depressive Disorder, Major as compared to allele G.	not stated	= 0.06	1167		European	Efficacy,Toxicity	false	p may not be significant after correction for testing of two SNPs.  The uncorrected p listed in the abstract = 0.02, but in table II it is listed as 0.03(corrected p = 0.04 or 0.6).   Number genotyped is at least 1167(1206 were successfully typed for at least one locus and 1167 were successfully typed for both).	citalopram
637880298	rs7997012	PMID:17671280	HTR2A	Allele A is associated with increased likelihood of response when treated with citalopram in people with Depression as compared to allele G.	yes	= 7.91E-4	1199		Multiple groups	Efficacy	false		citalopram
655386848	rs1799889	PMID:18794724	SERPINE1	Allele G is associated with decreased response to citalopram and fluoxetine in people with Depressive Disorder, Major as compared to allele A.	yes	= 0.014	140		East Asian	Efficacy	false	(as part of haplotype with rs2227631-G)	citalopram; fluoxetine
1183619708	CYP2C19*1; CYP2C19*2; CYP2C19*3	PMID:12975335	CYP2C19	CYP2C19 *2/*2 + *2/*3 is associated with increased citalopram AUC and terminal elimination half-life when treated with citalopram in healthy individuals as compared to CYP2C19 *1/*1 + *1/*2.	yes	= 0.01	13		East Asian	Metabolism/PK	false	"Eight extensive metabolizers (genotyped as CYP2C19*1/*1, CYP2C19*1/*2, or
CYP2C19*1/*3) and five poor metabolizers (genotyped as CYP2C19*2/*2 or
CYP2C19*2/*3) were randomly selected for participation in the study."	citalopram
1183847009	CYP2C19*1; CYP2C19*2	PMID:19840783	CYP2C19	CYP2C19 *1/*2 + *2/*2 is associated with increased AUC of citalopram when treated with citalopram in healthy individuals as compared to CYP2C19 *1/*1.	yes	= 0.007	35		European	Metabolism/PK	false		citalopram
1184513643	SLC6A4 HTTLPR long form (L allele); SLC6A4 HTTLPR short form (S allele)	PMCID:PMC2660379	SLC6A4	SLC6A4 HTTLPR long form (L allele)/HTTLPR long form (L allele) is associated with increased likelihood of remission when treated with citalopram in people with Depressive Disorder, Major as compared to SLC6A4 HTTLPR short form (S allele).	yes	= 0.024	1074		European	Efficacy	false	Remission was defined as a score of </= 5 on the 16-item Quick Inventory of Depressive Symptomatology-Clinician Rating (QIDS-C16) scale at the last clinic visit.	citalopram
1448112033	rs6296	PMID:27324805	HTR1B	Genotype CC is associated with increased risk of agitation when treated with citalopram in children with Anxiety Disorders or Depressive Disorder, Major as compared to genotypes CG + GG.	yes	= 0.011	87		Near Eastern	Toxicity	true	Study participants were diagnosed with major depression/dysthmymia or anxiety disorder according to the diagnostic and statistical manual of mental disorders, 4th edition. Patients were assessed at intake, 2, 4, 6, and 8 weeks.	citalopram
981500787	rs1360780	PMID:20709156	FKBP5	Allele T is not associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele C.	no	= 0.36	2302	1210	European	Efficacy	false	"One of the studies included in this meta-analysis was a ""Naturalistic pharmacogenetic study""."	citalopram; fluoxetine; mirtazapine; paroxetine; Selective serotonin reuptake inhibitors; venlafaxine
982015355	rs1360780	PMID:17467808	FKBP5	Allele T is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to allele C.	no				European	Efficacy	false	"This finding, though not significant,  is mentioned as being a failure to replicate previous findings in a German population(PMID:15565110). The OR entered is for increased risk of non-response.  Authors note that Bonferroni correction was not done and that they think that it would be overly conservative to do so.  p entered is not corrected; 7 SNPs were tested. Number of ""cases"" and ""controls"" entered are responders and non-responders."	citalopram
981476212	rs2235067	PMID:18215618	ABCB1	Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C.	yes	= 0.0071	280		European	Efficacy	false	Association was significant after correction for multiple testing at 4 weeks, but not so at 5 or 6 weeks.  It's not completely clear which allele was associated with remission or which sets of alleles/genotypes were compared.  I am entering the minor allele (in European populations) as the associated one.	amitriptyline; citalopram; paroxetine; venlafaxine
1184749158	rs363371	PMID:18797399	SLC18A2	Allele A is not associated with response to citalopram in people with Depressive Disorder, Major as compared to allele G.	no	> 0.05	730		European	Efficacy	false	No significant differences in the number of patients who were classified as nonresponders, responders or remitters were seen between either the genotypes (AA, AG, GG) or the alleles (A, G), in either European American or African American populations. Remitters achieved a Quick Inventory for Depression Scale, Change 16 Item version (QIDS-C16) score of <= 5 at the last treatment visit. Responders achieved at least a 50% reduction in baseline QIDS-C16 score at the last treatment visit. Nonresponders did not achieve even a 40% reduction in baseline QIDS-C16 score.	citalopram
982015348	rs2270007	PMID:17467808	CRHR2	Genotypes CC + CG are associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype GG.	yes	= 0.006	95	51	European	Efficacy	false	"This association is for response at week 4 but not at week 12.  The allele associated with worse response is described as G.  This is a G/C SNP, so this is ambiguous.  The gene is on the negative chromosomal strand, so I am guessing that the authors meant negative chromosomal strand G (= positive chromosomal strand C).  The OR entered is for increased risk of non-response.  Authors note that Bonferroni correction was not done and that they think that it would be overly conservative to do so.  p entered is not corrected; 7 SNPs were tested. Number of ""cases"" and ""controls"" entered are responders and non-responders."	citalopram
1183847020	CYP2D6*1; CYP2D6*4	PMID:19840783	CYP2D6	CYP2D6 *1/*4 is associated with increased AUC of citalopram when treated with citalopram in healthy individuals as compared to CYP2D6 *1/*1.	yes	= 0.031	35		European	Metabolism/PK	false		citalopram
981500798	rs3800373	PMID:20709156	FKBP5	Allele C is not associated with increased response to citalopram, fluoxetine, mirtazapine, paroxetine, Selective serotonin reuptake inhibitors or venlafaxine in people with Mood Disorders as compared to allele A.	no	= 0.09	2082	1108	European	Efficacy	false	"One of the studies included in this meta-analysis was a ""Naturalistic pharmacogenetic study""."	citalopram; fluoxetine; mirtazapine; paroxetine; Selective serotonin reuptake inhibitors; venlafaxine
1183701619	CYP2D6 poor metabolizer	PMID:8451774	CYP2D6	CYP2D6 poor metabolizer is associated with decreased demethylation clearance of desmethylcitalopram when treated with citalopram in healthy individuals as compared to CYP2D6 normal metabolizer.	yes	< 0.0001	18		European	Metabolism/PK	false		citalopram
1183619955	CYP2C19*1; CYP2C19*2; CYP2C19*3; CYP2C19*17	PMCID:PMC2268970	CYP2C19	CYP2C19 *2 + *3 +*17 are not associated with differences in remission or tolerance when treated with citalopram in people with Depressive Disorder, Major as compared to CYP2C19 *1.	no		1046		Multiple groups	Efficacy,Toxicity	false	CYP2C19 variants (*2, *3, *17)	citalopram
981862265	rs760761	PMID:19065121	DTNBP1	Allele A is associated with increased response to citalopram in people with Depressive Disorder, Major as compared to allele G.	no	= 0.028	147		European	Efficacy	false	The association is for response at 4 weeks. Allele distribution of SNP rs760761, however, showed a trend of difference between responders and nonresponders (4th week).	citalopram